75 related articles for article (PubMed ID: 12476293)
1. Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Feliu J; Clay J; Raj K; Barber L; Devlia V; Shaw B; Pagliuca A; Mufti G
Br J Haematol; 2014 Nov; 167(3):426-8. PubMed ID: 24962133
[No Abstract] [Full Text] [Related]
2. New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia.
Jordaens S; Cooksey L; Freire Boullosa L; Van Tendeloo V; Smits E; Mills KI; Orchard KH; Guinn BA
Cancer Immunol Immunother; 2020 May; 69(5):867-877. PubMed ID: 31970440
[TBL] [Abstract][Full Text] [Related]
3. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
4. Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
Piccaluga PP; Malagola M; Rondoni M; Amabile M; Paolini S; Soverini S; Gaitani S; Visani G; Baccarani M; Martinelli G
Eur J Haematol; 2004 Apr; 72(4):302-3. PubMed ID: 15089772
[No Abstract] [Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
[TBL] [Abstract][Full Text] [Related]
6. Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias.
Gupta V; Kamel-Reid S; Minden MD; Lipton JH; Brandwein J; Messner HA
Hematology; 2003 Jun; 8(3):139-43. PubMed ID: 12745646
[TBL] [Abstract][Full Text] [Related]
7. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
8. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hoelzer D; Gökbuget N; Ottmann OG
Semin Hematol; 2002 Oct; 39(4 Suppl 3):32-7. PubMed ID: 12447850
[TBL] [Abstract][Full Text] [Related]
10. [The role of imatinib in the treatment of acute lymphoid leukemias].
Poros A; Lovas N
Orv Hetil; 2005 May; 146(18 Suppl 1):905-10. PubMed ID: 15921303
[TBL] [Abstract][Full Text] [Related]
11. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
12. Imatinib for relapsed BCR/ABL positive leukemias.
Ottmann OG; Wassmann B; Hoelzer D
Ann Hematol; 2002; 81 Suppl 2():S36-7. PubMed ID: 12611069
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]